Substrate analog interaction with MCR-1 offers insight into the rising threat of the plasmid-mediated transferable

Pengcheng Wei1, Guangji Song1, Mengyang Shi1

  • 1State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, Department of Biochemistry and Molecular Biology, College of Life Sciences, Wuhan University, Wuhan, China.

Insights

The mobilized colistin resistance (mcr-1) gene confers resistance to last-resort antibiotics. Understanding MCR-1

Area of Science:

  • Microbiology
  • Structural Biology
  • Drug Discovery

Background:

  • Colistin is a critical last-resort antibiotic for treating gram-negative bacterial infections.
  • The emergence of plasmid-mediated colistin resistance, driven by the mcr-1 gene, poses a significant threat due to pan-drug-resistant bacteria.
  • The MCR-1 protein mediates resistance by transferring phosphoethanolamine (PEA) to lipid A, but its mechanism is not fully understood.

Purpose of the Study:

  • To elucidate the structural mechanism of the MCR-1 enzyme.
  • To identify potential drug targets and develop novel therapeutic strategies against MCR-1-mediated colistin resistance.

Main Methods:

  • X-ray crystallography was used to determine the structure of the MCR-1 catalytic domain (cMCR-1).
  • Cocrystallization of cMCR-1 with substrate analogs, including ethanolamine (ETA) and d-glucose, was performed.
  • Site-directed mutagenesis was employed to assess the role of key residues in colistin resistance.

Main Results:

  • Crystal structures revealed cMCR-1 as a monozinc metalloprotein with distinct binding pockets for ETA and d-glucose.
  • Mutations in ETA- and d-glucose-binding residues significantly reduced colistin resistance in bacteria expressing full-length MCR-1.
  • The substrate analog ETA demonstrated inhibition of polymyxin B resistance, indicating its therapeutic potential.

Conclusions:

  • The study highlights the critical roles of PEA- and lipid A-binding pockets in MCR-1 function.
  • Structural insights provide a basis for developing new drugs targeting MCR-1.
  • Addressing MCR-1-mediated resistance is crucial to combat the growing threat of pan-drug-resistant bacteria.